New hope for kids with psoriasis: cosentyx® shows promise in chinese study
NCT ID NCT05388916
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx® (secukinumab) for up to 52 weeks. The goal was to see how safe and effective the drug is in real-world settings. Researchers tracked side effects and measured how much the psoriasis improved using a standard skin score.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guangzhou, Guangdong, 510091, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 050000, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450018, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110004, China
-
Novartis Investigative Site
Xian, Shanxi, 710004, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310009, China
-
Novartis Investigative Site
Beijing, 100069, China